Current:Home > reviewsFDA approves first cell therapy to treat aggressive forms of melanoma -Profound Wealth Insights
FDA approves first cell therapy to treat aggressive forms of melanoma
Surpassing Quant Think Tank Center View
Date:2025-04-11 11:09:26
The Food and Drug Administration has approved a novel type of cancer therapy to treat aggressive forms of melanoma using immune system cells from a patient's tumor.
The treatment, called Amtagvi, was developed by Iovance Biotherapeutics, a biotech company based in San Carlos, Calif.
It is intended for patients whose melanoma cannot be removed with surgery or has spread to other parts of the body.
"The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a novel T cell immunotherapy for patients with limited treatment options," Dr. Peter Marks, the director of the FDA's Center for Biologics Evaluation and Research, said in a statement announcing the approval on Friday.
Melanoma develops when the skin cells that produce pigment start to grow out of control, according to the American Cancer Society. A major risk factor is exposure to ultraviolent light, which typically comes from the sun or tanning beds.
The tumor is easy to treat when detected early. But if it's not removed in time, melanoma can quickly spread to other parts of the body.
Amtagvi is designed to fight off advanced forms of melanoma by extracting and replicating T cells derived from a patient's tumor. T cells are part of the immune system. While they can typically help fight cancer, they tend to become dysfunctional inside tumors.
The newly approved medicine is similar to CAR-T, which is mainly used to treat blood cancers. Amtagvi is the first cell therapy approved by the FDA for solid tumors.
Amtagvi was fast-tracked through the FDA's accelerated approval pathway, a program to give patients with urgent, life-threatening illnesses early access to promising treatments.
Although Amtagvi was given the greenlight, Iovance Biotherapeutics said it is in the process of conducting an additional trial to confirm the treatment's efficacy, which is required by the FDA.
Melanoma only accounts for 1% of all skin cancer cases but it has been linked to a "significant number" of cancer-related deaths, according to the FDA.
The American Cancer Society estimates that in 2024, about 100,000 new cases of melanoma will be diagnosed and about 8,000 people will die from the skin cancer.
veryGood! (3862)
Related
- Civic engagement nonprofits say democracy needs support in between big elections. Do funders agree?
- Alaska Chokes on Wildfires as Heat Waves Dry Out the Arctic
- 10 Cooling Must-Haves You Need if It’s Too Hot for You To Fall Asleep
- Arctic National Wildlife Refuge Faces New Drilling Risk from Congress
- Newly elected West Virginia lawmaker arrested and accused of making terroristic threats
- Where gender-affirming care for youth is banned, intersex surgery may be allowed
- EPA’s ‘Secret Science’ Rule Meets with an Outpouring of Protest on Last Day for Public Comment
- This Week in Clean Economy: Northeast States Bucking Carbon Emissions Trend
- Which apps offer encrypted messaging? How to switch and what to know after feds’ warning
- Attacks on Brazil's schools — often by former students — spur a search for solutions
Ranking
- Mets have visions of grandeur, and a dynasty, with Juan Soto as major catalyst
- Rover Gas Pipeline Builder Faces Investigation by Federal Regulators
- Allergic to cats? There may be hope!
- U.S. Soldiers Falling Ill, Dying in the Heat as Climate Warms
- North Carolina trustees approve Bill Belichick’s deal ahead of introductory news conference
- 5 young women preparing for friend's wedding killed in car crash: The bright stars of our community
- Ticks! Ick! The latest science on the red meat allergy caused by some tick bites
- A deadly disease so neglected it's not even on the list of neglected tropical diseases
Recommendation
House passes bill to add 66 new federal judgeships, but prospects murky after Biden veto threat
Q&A: Plug-In Leader Discusses Ups and Downs of America’s E.V. Transformation
Q&A: Plug-In Leader Discusses Ups and Downs of America’s E.V. Transformation
This Week in Clean Economy: Pressure Is on Obama to Finalize National Solar Plan
New data highlights 'achievement gap' for students in the US
IPCC Report Shows Food System Overhaul Needed to Save the Climate
Today's election could weaken conservatives' long-held advantage in Wisconsin
Tony Bennett had 'a song in his heart,' his friend and author Mitch Albom says